menu_open Columnists
We use cookies to provide some features and experiences in QOSHE

More information  .  Close

The FDA Already Drew Line On China-Linked Experimental Drug. Now It Has To Enforce It

302 0
21.10.2026

In July, a 41-year-old woman went into cardiac arrest after taking retatrutide that a health care worker said came from an “unreliable source.” A second report followed in September. A 49-year-old patient had died of cardiac arrest after severe dehydration and malnutrition, having bought the drug online on a nurse’s recommendation. Both deaths were reported to the Food and Drug Administration (FDA), and CBS News obtained the records through a public records request.

Adverse event reports can’t establish a cause of death. Regulators are supposed to chase them anyway, and these two point to a product that should never have been on the market.

Retatrutide is Eli Lilly’s experimental weight-loss drug, still in clinical trials. Its early results were dramatic enough to create a market long before any approval. No country has cleared it for human use. The FDA says the drug “has not been found safe and effective for any condition,” and federal law bars pharmacies from compounding it.

I take a GLP-1 myself, so I understand the demand. According to Gallup, 11% of American adults now use one of these medications to lose weight, nearly four times the share in 2024. I’ve seen what they can do for a person’s health. I’ve also seen the bills. Brand-name........

© The Daily Caller